Cargando…
Microcurrent stimulation in the treatment of dry and wet macular degeneration
PURPOSE: To determine the safety and efficacy of the application of transcutaneous (transpalpebral) microcurrent stimulation to slow progression of dry and wet macular degeneration or improve vision in dry and wet macular degeneration. METHODS: Seventeen patients aged between 67 and 95 years with an...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689270/ https://www.ncbi.nlm.nih.gov/pubmed/26719667 http://dx.doi.org/10.2147/OPTH.S92296 |
_version_ | 1782406819778396160 |
---|---|
author | Chaikin, Laurie Kashiwa, Kellen Bennet, Michael Papastergiou, George Gregory, Walter |
author_facet | Chaikin, Laurie Kashiwa, Kellen Bennet, Michael Papastergiou, George Gregory, Walter |
author_sort | Chaikin, Laurie |
collection | PubMed |
description | PURPOSE: To determine the safety and efficacy of the application of transcutaneous (transpalpebral) microcurrent stimulation to slow progression of dry and wet macular degeneration or improve vision in dry and wet macular degeneration. METHODS: Seventeen patients aged between 67 and 95 years with an average age of 83 years were selected to participate in the study over a period of 3 months in two eye care centers. There were 25 eyes with dry age-related macular degeneration (DAMD) and six eyes with wet age-related macular degeneration (WAMD). Frequency-specific microcurrent stimulation was applied in a transpalpebral manner, using two programmable dual channel microcurrent units delivering pulsed microcurrent at 150 µA for 35 minutes once a week. The frequency pairs selected were based on targeting tissues, which are typically affected by the disease combined with frequencies that target disease processes. Early Treatment Diabetic Retinopathy Study or Snellen visual acuity (VA) was measured before and after each treatment session. All treatment was administered in a clinical setting. RESULTS: Significant increases were seen in VA in DAMD (P=0.012, Wilcoxon one-sample test), but in WAMD, improvements did not reach statistical significance (P=0.059). In DAMD eyes, twice as many patients showed increase in VA (52%) compared to those showing deterioration (26%), with improvements being often sizeable, whereas deteriorations were usually very slight. In WAMD eyes, five of six (83%) patients showed an increase and none showed deterioration. CONCLUSION: The substantial changes observed over this period, combined with continued improvement for patients who continued treatment once a month, are encouraging for future studies. The changes observed indicate the potential efficacy of microcurrent to delay degeneration and possibly improve age-related macular degeneration, both wet and dry. However, this study has no control arm, so results should be treated with caution. Randomized double-blind controlled studies are needed to determine long-term effects. |
format | Online Article Text |
id | pubmed-4689270 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-46892702015-12-30 Microcurrent stimulation in the treatment of dry and wet macular degeneration Chaikin, Laurie Kashiwa, Kellen Bennet, Michael Papastergiou, George Gregory, Walter Clin Ophthalmol Original Research PURPOSE: To determine the safety and efficacy of the application of transcutaneous (transpalpebral) microcurrent stimulation to slow progression of dry and wet macular degeneration or improve vision in dry and wet macular degeneration. METHODS: Seventeen patients aged between 67 and 95 years with an average age of 83 years were selected to participate in the study over a period of 3 months in two eye care centers. There were 25 eyes with dry age-related macular degeneration (DAMD) and six eyes with wet age-related macular degeneration (WAMD). Frequency-specific microcurrent stimulation was applied in a transpalpebral manner, using two programmable dual channel microcurrent units delivering pulsed microcurrent at 150 µA for 35 minutes once a week. The frequency pairs selected were based on targeting tissues, which are typically affected by the disease combined with frequencies that target disease processes. Early Treatment Diabetic Retinopathy Study or Snellen visual acuity (VA) was measured before and after each treatment session. All treatment was administered in a clinical setting. RESULTS: Significant increases were seen in VA in DAMD (P=0.012, Wilcoxon one-sample test), but in WAMD, improvements did not reach statistical significance (P=0.059). In DAMD eyes, twice as many patients showed increase in VA (52%) compared to those showing deterioration (26%), with improvements being often sizeable, whereas deteriorations were usually very slight. In WAMD eyes, five of six (83%) patients showed an increase and none showed deterioration. CONCLUSION: The substantial changes observed over this period, combined with continued improvement for patients who continued treatment once a month, are encouraging for future studies. The changes observed indicate the potential efficacy of microcurrent to delay degeneration and possibly improve age-related macular degeneration, both wet and dry. However, this study has no control arm, so results should be treated with caution. Randomized double-blind controlled studies are needed to determine long-term effects. Dove Medical Press 2015-12-17 /pmc/articles/PMC4689270/ /pubmed/26719667 http://dx.doi.org/10.2147/OPTH.S92296 Text en © 2015 Chaikin et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Chaikin, Laurie Kashiwa, Kellen Bennet, Michael Papastergiou, George Gregory, Walter Microcurrent stimulation in the treatment of dry and wet macular degeneration |
title | Microcurrent stimulation in the treatment of dry and wet macular degeneration |
title_full | Microcurrent stimulation in the treatment of dry and wet macular degeneration |
title_fullStr | Microcurrent stimulation in the treatment of dry and wet macular degeneration |
title_full_unstemmed | Microcurrent stimulation in the treatment of dry and wet macular degeneration |
title_short | Microcurrent stimulation in the treatment of dry and wet macular degeneration |
title_sort | microcurrent stimulation in the treatment of dry and wet macular degeneration |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689270/ https://www.ncbi.nlm.nih.gov/pubmed/26719667 http://dx.doi.org/10.2147/OPTH.S92296 |
work_keys_str_mv | AT chaikinlaurie microcurrentstimulationinthetreatmentofdryandwetmaculardegeneration AT kashiwakellen microcurrentstimulationinthetreatmentofdryandwetmaculardegeneration AT bennetmichael microcurrentstimulationinthetreatmentofdryandwetmaculardegeneration AT papastergiougeorge microcurrentstimulationinthetreatmentofdryandwetmaculardegeneration AT gregorywalter microcurrentstimulationinthetreatmentofdryandwetmaculardegeneration |